参芎葡萄糖注射液对中、重度慢性阻塞性肺疾病患者气道中转化生长因子β1作用的研究  

Effect of Shenxiong glucose injection on transforming growth factor-IS1 in airway of middle and

作　　者：朱莉莉[1] 刘磊[1] 李玉梅[1] 李玉[1] 陈勐[1] 刘博[1] 秦丹丹[2] 李桂兰[1] 郑岩[1] 

机构地区：[1]哈尔滨医科大学附属第四医院呼吸内科一病房,150001 [2]哈尔滨医科大学附属第四医院呼吸内科肺功能室,150001

出　　处：《中国医师进修杂志》2014年第13期14-16,共3页Chinese Journal of Postgraduates of Medicine

基　　金：黑龙江省自然科学基金（D201146）

摘　　要：目的评价参芎葡萄糖注射液对中、重度慢性阻塞性肺疾病（COPD）患者气道中转化生长因子β1（TGF—β1）的影响。方法将64例中、重度COPD患者按随机数字表法分为参芎葡萄糖组（42例）和对照组（22例），两组均给予COPD的常规治疗，参芎葡萄糖组加用参芎葡萄糖注射液，对照组加用5％葡萄糖注射液，其治疗3个疗程。采用酶联免疫吸附法测定两组治疗前及每个疗程治疗后痰中TGF—β1。结果参芎葡萄糖组和对照组治疗前痰中TGF—β1比较差异无统计学意义[（95．4±8．1）μg／L比（94．8±7．5）μg／L，P〉0．05]。治疗第1个疗程后，参芎葡萄糖组痰中TGF—β1[（85．5±5．2）μg／L]较治疗前有所下降，但差异无统计学意义（P〉O．05）；治疗第2，3个疗程后，参芎葡萄糖组痰中TGF—β1较治疗前显著下降[（61．5±5．8）、（49．1±4．5）μg／L]，且显著低于同期对照组[（89．6±6-2）、（91．2±6．2）μg／L]，差异有统计学意义（P〈0．05）。对照组治疗第1，2，3个疗程后痰中TGF—β1与治疗前比较差异无统计学意义（P〉0．05）。参芎葡萄糖组治疗过程中未发现明显药物不良反应（包括肝肾功能异常）。结论参芎葡萄糖注射液一定疗程后可显著降低中、重度COPD患者气道中TGF-β1表达，可能会减轻气道重塑反应。Objective To investigate the effect of Shenxiong glucose injection on transforming growth factor-β1 (TGF-β1) in airway of middle and serious chronic obstructive pulmonary disease (COPD).Methods A total of 64 patients with middle and serious COPD were divided into Shenxiong glucose group (42 cases) and control group (22 cases) by random digits table method.Conventional therapy of COPD was given in two groups.The patients in Shenxiong glucose group were treated by Shenxiong glucose injection and the patients in control group were treated by 5 percent glucose injection for 3 courses.TGF-β1 was measured before treatment and after each course in two groups by enzyme linked immunosorbent assay.Results There was no significant difference in TGF-β1 level of phlegm before treatment between two groups [(95.4 ± 8.1)μg/L vs.(94.8 ± 7.5) μg/L,P ＞ 0.05].TGF-β1 level of phlegm was decreased after 1 course [(85.5 ± 5.2)μg/L] compared with that before treatment in Shenxiong glucose group,but there was no significant difference (P ＞ 0.05).TGF-β1 level of phlegm was decreased after 2,3 courses [(61.5 ± 5.8),(49.1 ± 4.5)μg/L] compared with that before treatment,which was lower than that in control group [(89.6 ± 6.2),(91.2 ±6.2) μg/L],and there was significant difference (P＜ 0.05).There was no significant difference in TGF-β1 level of phlegm after 1,2,3 courses in control group,compared with that before treatment (P ＞0.05).The adverse reaction (including liver and kidney dysfunction) was not found in Shenxiong glucose group.Conclusion Shenxiong glucose injection has significant effect on TGF-β1 level of phlegm in patients with COPD at certain courses,and improve airway remodeling in patients with COPD at certain courses.

关 键 词：肺疾病 慢性阻塞性 转化生长因子Β1 参芎葡萄糖注射液 

分 类 号：R563.9[医药卫生—呼吸系统]